Lack of mitigation of methamphetamine-induced neurotoxicity by ganglioside GM1 or vitamin E.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism; D005677:G(M1) Ganglioside / Q000494:pharmacology*; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008694:Methamphetamine / Q000037:antagonists & inhibitors / Q000633:toxicity*; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009498:Neurotoxins / Q000037:antagonists & inhibitors / Q000633:toxicity*; D017382:Reactive Oxygen Species / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D014810:Vitamin E / Q000494:pharmacology*
D018696:Neuroprotective Agents; D009498:Neurotoxins; D017382:Reactive Oxygen Species; D015102:3,4-Dihydroxyphenylacetic Acid; D014810:Vitamin E; D012701:Serotonin; D005677:G(M1) Ganglioside; D008694:Methamphetamine; D006897:Hydroxyindoleacetic Acid; D004298:Dopamine; D006719:Homovanillic Acid